Literature DB >> 33726773

Identification of potential markers for differentiating epithelial ovarian cancer from ovarian low malignant potential tumors through integrated bioinformatics analysis.

Wende Hao1, Hongyu Zhao1, Zhefeng Li1, Jie Li1, Jiahao Guo1, Qi Chen1, Yan Gao1, Meng Ren1, Xiaoting Zhao2, Wentao Yue3.   

Abstract

BACKGROUND: Epithelial ovarian cancer (EOC), as a lethal malignancy in women, is often diagnosed as advanced stages. In contrast, intermediating between benign and malignant tumors, ovarian low malignant potential (LMP) tumors show a good prognosis. However, the differential diagnosis of the two diseases is not ideal, resulting in delays or unnecessary therapies. Therefore, unveiling the molecular differences between LMP and EOC may contribute to differential diagnosis and novel therapeutic and preventive policies development for EOC.
METHODS: In this study, three microarray data (GSE9899, GSE57477 and GSE27651) were used to explore the differentially expressed genes (DEGs) between LMP and EOC samples. Then, 5 genes were screened by protein-protein interaction (PPI) network, receiver operating characteristic (ROC), survival and Pearson correlation analysis. Meanwhile, chemical-core gene network construction was performed to identify the potential drugs or risk factors for EOC based on 5 core genes. Finally, we also identified the potential function of the 5 genes for EOC through pathway analysis.
RESULTS: Two hundred thirty-four DEGs were successfully screened, including 81 up-regulated genes and 153 down-regulated genes. Then, 5 core genes (CCNB1, KIF20A, ASPM, AURKA, and KIF23) were identified through PPI network analysis, ROC analysis, survival and Pearson correlation analysis, which show better diagnostic efficiency and higher prognostic value for EOC. Furthermore, NetworkAnalyst was used to identify top 15 chemicals that link with the 5 core genes. Among them, 11 chemicals were potential drugs and 4 chemicals were risk factors for EOC. Finally, we found that all 5 core genes mainly regulate EOC development via the cell cycle pathway by the bioinformatic analysis.
CONCLUSION: Based on an integrated bioinformatic analysis, we identified potential biomarkers, risk factors and drugs for EOC, which may help to provide new ideas for EOC diagnosis, condition appraisal, prevention and treatment in future.

Entities:  

Keywords:  Chemicals; Diagnosis; Epithelial ovarian cancer; Integrated bioinformatical analysis; Low malignant potential tumor; Prognosis

Year:  2021        PMID: 33726773      PMCID: PMC7968266          DOI: 10.1186/s13048-021-00794-0

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


  69 in total

1.  A plus-end-directed motor enzyme that moves antiparallel microtubules in vitro localizes to the interzone of mitotic spindles.

Authors:  C Nislow; V A Lombillo; R Kuriyama; J R McIntosh
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

2.  Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.

Authors:  Tong Li; Yimin Li; Yaqi Gan; Ruotong Tian; Qihan Wu; Guang Shu; Gang Yin
Journal:  Cell Cycle       Date:  2019-06-09       Impact factor: 4.534

3.  The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein.

Authors:  Natalay Kouprina; Adam Pavlicek; N Keith Collins; Megumi Nakano; Vladimir N Noskov; Jun-Ichirou Ohzeki; Ganeshwaran H Mochida; John I Risinger; Paul Goldsmith; Michelle Gunsior; Greg Solomon; William Gersch; Jung-Hyun Kim; J Carl Barrett; Christopher A Walsh; Jerzy Jurka; Hiroshi Masumoto; Vladimir Larionov
Journal:  Hum Mol Genet       Date:  2005-06-22       Impact factor: 6.150

Review 4.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

5.  Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.

Authors:  Camille Maringe; Sarah Walters; John Butler; Michel P Coleman; Neville Hacker; Louise Hanna; Berit J Mosgaard; Andy Nordin; Barry Rosen; Gerda Engholm; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Colleen E McGahan; David Meechan; Richard Middleton; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet
Journal:  Gynecol Oncol       Date:  2012-06-27       Impact factor: 5.482

6.  The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.

Authors:  Fei Fei; Jie Qu; Kai Liu; Chunyuan Li; Xinlu Wang; Yuwei Li; Shiwu Zhang
Journal:  Lab Invest       Date:  2018-11-28       Impact factor: 5.662

7.  ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.

Authors:  Shih-Yeh Lin; Hung-Wei Pan; Shu-Hsiang Liu; Yung-Ming Jeng; Fu-Chang Hu; Shian-Yang Peng; Po-Lin Lai; Hey-Chi Hsu
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

8.  The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis.

Authors:  Chung-Chi Hsu; Wen-Ying Liao; Tze-Sian Chan; Wei-Yu Chen; Chung-Ta Lee; Yan-Shen Shan; Po-Jui Huang; Ya-Chin Hou; Chi-Rong Li; Kelvin K Tsai
Journal:  J Pathol       Date:  2019-10-23       Impact factor: 7.996

Review 9.  Controversies in borderline ovarian tumors.

Authors:  Seok Ju Seong; Da Hee Kim; Mi Kyoung Kim; Taejong Song
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

10.  Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.

Authors:  Zheng Zhang; Ciman Chai; Tianyu Shen; Xiaoqing Li; Junpeng Ji; Changying Li; Zhiqun Shang; Yuanjie Niu
Journal:  Dis Markers       Date:  2019-09-03       Impact factor: 3.434

View more
  1 in total

1.  Abnormal spindle-like microcephaly-associated protein promotes proliferation by regulating cell cycle in epithelial ovarian cancer.

Authors:  Yiguo Wu; Yujuan You; Ling Chen; Yue Liu; Yujuan Liu; Weiming Lou; Fen Fu
Journal:  Gland Surg       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.